Hizentra (Human Normal Immunoglobulin)

Hizentra is indicated for the treatment and prevention of infections in patients with certain immune disorders. It is administered as part of a regular replacement regimen.

• Primary immunodeficiency diseases (e.g., common variable immunodeficiency, X‑linked agammaglobulinemia)
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Secondary antibody deficiency associated with hematologic malignancies
• Patients requiring long‑term immunoglobulin replacement who prefer subcutaneous administration
• Maintenance therapy to reduce infection frequency and severity

• Human normal immunoglobulin in Hizentra provides passive immunity by supplying a broad spectrum of functional IgG antibodies that replace deficient endogenous immunoglobulins. The infused IgG binds to pathogens and toxins, facilitates opsonization, activates complement, and modulates immune cell activity, thereby enhancing host defense and reducing the risk of infection.

Adverse reactions to Hizentra are generally related to the subcutaneous route and the immunoglobulin content.

Common

• Injection site redness, swelling, or itching
• Headache
• Fatigue or malaise
• Nausea or mild gastrointestinal upset
• Low-grade fever

Serious

• Anaphylaxis or severe allergic reaction
• Thromboembolic events (e.g., deep vein thrombosis)
• Acute renal failure
• Hemolytic anemia
• Severe systemic infection

Before initiating Hizentra, clinicians should assess patient history and monitor for potential complications.

• Evaluate for known IgA deficiency or anti‑IgA antibodies, which may increase risk of severe reactions.
• Assess renal function, especially in patients with pre‑existing kidney disease.
• Monitor for signs of thromboembolic events during therapy.
• Use caution in patients with a history of cardiovascular disease or hypercoagulability.
• Counsel patients on proper injection technique to minimize local reactions.
• Discontinue if severe systemic allergic reactions occur.

Hizentra may interact with other agents that affect coagulation, immune response, or renal function.

Avoid

• Concurrent use of high‑dose anticoagulants or antiplatelet agents without close monitoring.
• Simultaneous administration of other immunoglobulin products, which can increase viscosity.

Use with caution

• Live vaccines, as passive antibodies may interfere with vaccine efficacy.
• Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) due to potential additive renal stress.
• Medications that alter platelet function (e.g., aspirin, clopidogrel).
• Therapies that modulate the immune system, such as monoclonal antibodies.
• Intravenous fluids that may affect volume status.